RxSight (RXST) EBITDA Margin (2020 - 2026)
RxSight (RXST) posted EBITDA Margin of 57.71% for Q1 2026, down 66.54% on a QoQ basis from 34.65% in Q4 2025, and down 2954.0% year-over-year from 2.02% in Q1 2025.
RxSight (RXST) EBITDA Margin (2020 - 2026) Analysis & Trends
RxSight's EBITDA Margin history runs 7 years deep, the most recent figure standing at 57.71% for Q1 2026.
- Quarterly EBITDA Margin fell 2954.0% year-over-year to 57.71% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 43.4% (down 1854.0% YoY) and the FY2025 annual result came in at 35.84%, down 947.0% from the prior year.
- EBITDA Margin was 57.71% for Q1 2026 at RxSight, down from 34.65% in the prior quarter.
- Across five years, EBITDA Margin topped out at 139.08% in Q2 2022 and bottomed at 312.46% in Q4 2023.
- A 5-year average of 32.42% and a median of 34.65% in 2025 frame the typical range for EBITDA Margin.
- Peak annual rise in EBITDA Margin reached 42246 bps in 2022, while the deepest fall reached 117226 bps in 2022.
- RxSight's EBITDA Margin stood at 93.18% in 2022, then plunged by 235 bps to 312.46% in 2023, then surged by 93 bps to 21.56% in 2024, then slumped by 61 bps to 34.65% in 2025, then plunged by 67 bps to 57.71% in 2026.
- Business Quant data shows RXST's EBITDA Margin at 57.71% in Q1 2026, 34.65% in Q4 2025, and 40.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 12.05% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 15.55% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 19.10% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 21.16% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 28.97% |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 21.42% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 6.17% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 10.04% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | RxSight | 221.81 Mn | -196.39 Mn | 23.50 Mn | -57.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.71% |
| Dec 31, 2025 | -34.65% |
| Sep 30, 2025 | -40.21% |
| Jun 30, 2025 | -41.62% |
| Mar 31, 2025 | -28.17% |
| Dec 31, 2024 | -21.56% |
| Sep 30, 2024 | -26.13% |
| Jun 30, 2024 | -23.79% |
| Mar 31, 2024 | -36.15% |
| Dec 31, 2023 | -312.46% |
| Sep 30, 2023 | -56.36% |
| Jun 30, 2023 | 65.35% |
| Mar 31, 2023 | 74.90% |
| Dec 31, 2022 | -93.18% |
| Sep 30, 2022 | 126.83% |
| Jun 30, 2022 | 139.08% |
| Mar 31, 2022 | -185.39% |
| Dec 31, 2021 | 1,079.09% |
| Sep 30, 2021 | 226.41% |
| Jun 30, 2021 | -283.38% |